The prevalence of older patients with acquired thrombotic thrombocytopenic purpura (TTP) has increased as a consequence of significant improvements in disease diagnosis and drug availability. Patient aging may be challenging for the traditional disease management, which may be affected by the concomitant presence of different age-related diseases and polypharmacy. The growing prevalence of concomitant chronic disease in acquired TTP patients is not only an age-related effect, because a positive history of one or more TTP episodes may increase the risk of developing other diseases, so that a continuous and long-term follow-up of these patients is recommended after clinical remission.
